Amgen Inc. v. International Trade Commission

Federal Circuit

Amgen Inc. v. International Trade Commission

564 F.3d 1358, 90 U.S.P.Q. 2d (BNA) 1842, 31 I.T.R.D. (BNA) 1984, 2009 U.S. App. LEXIS 9409, 2009 WL 1152018

CourtCourt of Appeals for the Federal Circuit

DecidedApril 30, 2009

DocketNo. 2007-1014

StatusPublished

This text of 564 F.3d 1358 (Amgen Inc. v. International Trade Commission) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Amgen Inc. v. International Trade Commission, 564 F.3d 1358, 90 U.S.P.Q. 2d (BNA) 1842, 31 I.T.R.D. (BNA) 1984, 2009 U.S. App. LEXIS 9409, 2009 WL 1152018 (Fed. Cir. 2009).

Pincite

Opinion

ORDER

PER CURIAM.

This case was heard by a panel of three judges. Combined petitions for panel rehearing and rehearing en banc were filed by the International Trade Commission and Roche Holding Ltd., F. Hoffmann-La Roche, Ltd., Roche Diagnostics GmbH, and Hoffman-La Roche, Inc. A response was invited by the court and filed by Am-gen Inc. The petition for rehearing en banc and response having been referred to the circuit judges who are in regular active service, and a poll having been requested and taken,

IT IS ORDERED THAT:

Rehearing en banc is granted for the limited purpose of authorizing the panel to revise part II of its opinion.

The judgment of the court entered on March 19, 2008, and reported at 519 F.3d 1343, is hereby vacated, and the opinion of the court accompanying the judgment is withdrawn.

The en banc court returns this appeal to the merits panel, which issues the revised opinion that accompanies this order.

Free access — add to your briefcase to read the full text and ask questions with AI